40 citations
,
April 2018 in “Endocrine” This review discusses post-SSRI sexual dysfunction and post-finasteride syndrome, highlighting unknowns about their true incidence and underlying causes, and reports no new clinical results.
20 citations
,
September 2019 in “Epidemiology and Psychiatric Sciences” This review discusses post-SSRI sexual dysfunction syndrome and highlights its significant clinical and regulatory implications, but reports no new findings.
11 citations
,
April 2023 in “Annals of General Psychiatry” This study found that males treated with serotonergic antidepressants had an increased risk of erectile dysfunction, with an adjusted odds ratio of 3.2, and the risk for post-SSRI sexual dysfunction was 0.46%, emphasizing the importance of informed consent due to these potential irreversible side effects.
July 2023 in “Zenodo (CERN European Organization for Nuclear Research)” In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.
July 2023 in “World Journal of Biology Pharmacy and Health Sciences” This research suggests that the drugs trazodone and chlorpromazine, which have effects on specific receptors, may help restore libido synaptic circuits and potentially treat sexual dysfunction associated with post-SSRI and post-finasteride syndromes.
